

Announcement

EURADOS ICIDOSE#2

InterComparison of Internal DOSE assessment #2

Introduction

Internal dose assessment intercomparison exercises offer several advantages. They aid in verifying the performance of an internal dosimetry service, promote the harmonization of dose assessments, and identify areas for improvement. In 2017, the Internal Dosimetry Group (WG7) of EURADOS organized an intercomparison named ICIDOSE 2017. The primary aim of this initiative was to test the practical applicability of new technical recommendations issued by the European Commission (RP188). A second intercomparison, ICIDOSE#2, is scheduled for 2024 and will once again be organized by EURADOS WG7.

Scope

The objective of ICIDOSE#2 is for participants to assess internal dose according to either the most recent recommendations (RP188, ICRP OIR Report Series) or to the standards for accreditation. The exercise consists of five different cases, varying in complexity from simple to more challenging scenarios. This approach is designed to address common issues encountered routinely or more seldom in internal dosimetry.

Intercomparison procedure

Upon registration participants will be issued an identifier code enabling access to a website, where instructions for participants, case descriptions for evaluation, and the required format(s) for result submission will be accessible. To ensure your participation, kindly reach out to us before 30/06/2024 with your expression of interest via the website: https://icidose.ek.hun-ren.hu.

The intercomparison includes five different cases, each posing its own set of challenges. These cases are as follows:

- a straightforward scenario involving Cs-137 whole-body counter measurements,
- a case study featuring data on thyroid and urine measurements for I-131,
- tritium in urine monitoring data over a period of several months,
- a case involving wounds contaminated with Pu-239, Pu-240, Am-241,
- a particularly unique scenario focusing on the inhalation of S-35 by a pregnant worker.

Some cases feature only a limited number of (early-phase) data points, whereas others have more extensive data available over extended periods. Moreover, dose assessments will rely on prolonged monitoring intervals, such as records covering an entire year. The intercomparison covers scenarios including dose assessments after routine monitoring, subsequent assessments following negative results, as well as considerations for new intakes necessitating special monitoring. Additionally, a special case is included, specifically designed to prompt a reevaluation of established methodologies.

Participants are not obliged to respond to all cases; instead, they may select the specific case(s) for which they would like to provide responses. Each participant is permitted to submit only one solution per case, but will be able to revise their previously submitted results until the submission deadline.

Intercomparison report

The Organization Group will prepare a report summarizing the results and key findings of the intercomparison.

The identifier, assigned to each participant and known solely to the Organization Group, will allow the results to be presented anonymously.

Participants have the opportunity to utilize their participation in the exercise to demonstrate the quality of their performance to the national competent authority.

Final workshop

A dedicated workshop will focus on presenting and discussing the results with both the Organization Group and all participants. The specific date and venue for this meeting will be announced at a later time.

Time schedule

Milestones	Date
Announcement of ICIDOSE#2	01/04/2024
Deadline for expressing interest in participating in ICIDOSE#2	30/06/2024
Start of availability of case descriptions, instructions and forms for	01/09/2024
download on the ICIDOSE#2 website	
Deadline for submitting case evaluations	30/11/2024
Release of preliminary overall results	31/01/2025
Conclusion of the evaluation of results	30/03/2025
Workshop for ICIDOSE#2 participants	Spring of 2025
Publication of the Intercomparison Report	31/08/2025

Organization Group

Name	Organization	Country
Derek BINGHAM	AWE	United Kingdom
Bastian BREUSTED	KIT	Germany
David BROGGIO	IRSN	France
Guillaume DROUET	IRSN	France
Pavel FOJTIK	SURO	Czech Republic
Augusto GIUSSANI	BfS	Germany
Simone LÖSCHER	BfS	Germany
Jakub OSKO	NCBJ	Poland
Anna PÁNTYA	HUN-REN EK	Hungary
Tamás PÁZMÁNDI	HUN-REN EK	Hungary
Zsófia RÉKASI	HUN-REN EK	Hungary
Vendula ROVENSKÁ	SURO	Czech Republic
David SPENCER	Nuvia	United Kingdom

Contact persons

Tamás PÁZMÁNDI (pazmandi.tamas@ek.hun-ren.hu)
Anna PÁNTYA (pantya.anna@ek.hun-ren.hu)